Emodin potentiates the antiproliferative effect of interferon α/β by activation of JAK/STAT pathway signaling through inhibition of the 26S proteasome

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4664-4679

  He, Yujiao ^a   Huang, Junmei ^a,b   Wang, Ping ^b   Shen, Xiaofei ^a   Li, Sheng ^a   Yang, Lijuan ^a   Liu, Wanli ^d   Suksamrarn, Apichart ^c   Zhang, Guolin ^a,e   Wang, Fei ^a,e  

^a CHENGDU INSTITUTE OF BIOLOGY   (China)

^b CHENGDU UNIVERSITY   (China)

^c RAMKHAMHAENG UNIVERSITY   (Thailand)

^d TSINGHUA UNIVERSITY   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

26S proteasome; Emodin; Interferon; JAK STAT

Indexed keywords

26S PROTEASOME; ALPHA INTERFERON; BETA INTERFERON; BORTEZOMIB; CASPASE; CHYMOTRYPSIN; EMODIN; INTERFERON RECEPTOR; JANUS KINASE; PROTEASOME; RECOMBINANT ALPHA2A INTERFERON; SMALL INTERFERING RNA; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TYPE I INTERFERON RECEPTOR 1; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; ATP DEPENDENT 26S PROTEASE; MESSENGER RNA; PROTEIN KINASE INHIBITOR; STAT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TREATMENT OUTCOME; UBIQUITINATION; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; UTERINE CERVICAL NEOPLASMS; WESTERN BLOTTING;

ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; EMODIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTERFERON-ALPHA; INTERFERON-BETA; JANUS KINASES; LIVER NEOPLASMS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958019848     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6616     Document Type: Article

References (53)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR and Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007; 6:975-990.
2. Jonasch E and Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001; 6:34-55.
3. Tai Z, Lin Y, He Y, Huang J, Guo J, Yang L, Zhang G and Wang F. Luteolin sensitizes the antiproliferative effect of interferon a/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells. Cell Signal. 2014; 26:619-628.
4. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A, Helynck O, Caignard G, Janvier G, André-Leroux G, Khiar S, Escriou N, Desprès P, Jacob Y, et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog. 2013; 9:e1003678.
5. Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, Ashihara M, Hirata Y, Ohta A, Sakamoto H, Hada N, Katsume A, Kohara M, Morikawa K, et al. An orally available, small-molecule interferon inhibits viral replication. Sci Rep. 2012; 2: 259.
6. van Boxel-Dezaire AH, Rani MR and Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity. 2006; 25:361-372.
7. Kumar KG, Krolewski JJ and Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem. 2004; 279:46614-46620.
8. Ragimbeau J, Dondi E, Alcover A, Eid P, Uzé G and Pellegrini S. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 2003; 22:537-547.
9. Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS and Stephanou A. ERK and the F-box protein βTRCP target STAT1 for degradation. J Biol Chem. 2008; 283:16077-16083.
10. Didcock L, Young DF, Goodbourn S and Randall RE. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol. 1999; 73:9928-9933.
11. Lee Y, Hyung SW, Jung HJ, Kim HJ, Staerk J, Constantinescu SN, Chang EJ, Lee ZH, Lee SW and Kim HH. The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-β-induced inhibitory signaling. Blood. 2008; 111:885-893.
12. Srinivas G, Babykutty S, Sathiadevan PP and Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2007; 27:591-608.
13. Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS and Sethi G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett. 2013; 341:139-149.
14. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A, Pardanani A, Lin FT, Li J, Sha B and Benveniste EN. A CK2-dependent mechanism for activation of the JAKSTAT signaling pathway. Blood. 2011; 118:156-166.
15. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, Uchida T, Asakura K, Nakazato T, Kaneda T, Kizaki M, Ikeda Y and Yoshida T. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther. 2007; 6:987-994.
16. Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM and Sethi G. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 2013; 170:807-821.
17. Tai ZF, Zhang GL and Wang F. Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen. Biol Pharm Bull. 2012; 35:65-71.
18. Zhang M, Pickart CM and Coffino P. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitinindependent substrate. EMBO J. 2003; 22:1488-1496.
19. Erales J and Coffino P. Ubiquitin-independent proteasomal degradation. Biochim Biophys Acta. 2014; 1843:216-221.
20. Hoyt MA, Zhang M and Coffino P. Probing the ubiquitin/proteasome system with ornithine decarboxylase, a ubiquitin-independent substrate. Methods Enzymol. 2005; 398: 399-413.
21. Adams, J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4:349-360.
22. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487-2498.
23. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R and Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007; 13:5291-5294.
24. Richardson PG, Hideshima T and Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003; 10:361-369.
25. Kisselev AF, van der Linden WA and Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol. 2012; 19:99-115.
26. Rickardson L1, Wickström M, Larsson R and Lövborg H. Image-based screening for the identification of novel proteasome inhibitors. J Biomol Screen. 2007; 12:203-210.
27. Chang TL. Inhibitory effect of flavonoids on 26S proteasome activity. J Agric Food Chem. 2009; 57:9706-9715.
28. Mozzicafreddo M, Cuccioloni M, Cecarini V, Eleuteri AM and Angeletti M. Homology modeling and docking analysis of the interaction between polyphenols and mammalian 20S proteasomes. J Chem Inf Model. 2009; 49:401-409.
29. Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL and Kessler BM. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005; 65:7896-7901.
30. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010; 70:1970-1980.
31. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008; 111:2765-2775.
32. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005; 8:407-419.
33. Richman DD. Antiviral drug resistance. Antiviral Res. 2006; 71:117-21.
34. Lin Y, Wang F and Zhang GL. Natural products and their derivatives regulating the janus kinase/signal transducer and activator of transcription pathway. J Asian Nat Prod Res. 2014; 16:800-812.
35. Regis G, Pensa S, Boselli D, Novelli F and Poli V. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol. 2008; 19:351-359.
36. HOS ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-a receptor. EMBO J. 2003; 22:5480-5490.
37. Fuchs SY. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J Interferon Cytokine Res. 2013; 33:211-225.
38. Huang Q, Shen HM and Ong CN. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-κB. Biochem Pharmacol. 2004; 68:361-371.
39. Li HL, Chen HL, Li H, Zhang KL, Chen XY, Wang XW, Kong QY and Liu J. Regulatory effects of emodin on NF-κB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med. 2005; 16:41-47.
40. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A and Ben-Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1995; 92:10599-10603.
41. Shieh DE, Chen YY, Yen MH, Chiang LC and Lin CC. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci. 2004; 74:2279-2290.
42. Haupt Y, Maya R, Kazaz A and Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387:296-299.
43. Li M1, Brooks CL, Wu-Baer F, Chen D, Baer R and Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 2003; 302:1972-1975.
44. Huang Q, Lu G, Shen HM, Chung MC and Ong CN. Anticancer properties of anthraquinones from rhubarb. Med Res Rev. 2007; 27:609-630.
45. Taniguchi T and Takaoka A. A weak signal for strong responses: Interferon-a/β revisited. Nat Rev Mol Cell Bio. 2001; 2:378-386.
46. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE and Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol. 2002; 156:843-854.
47. Yu A and Malek TR. The proteasome regulates receptormediated endocytosis of interleukin-2. J Biol Chem. 2001; 276:381-385.
48. van Kerkhof P, Govers R, Alves dos Santos CM and Strous GJ. Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J Biol Chem. 2000; 275:1575-1580.
49. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR and Dou QP. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol. 2005; 69:1421-1432.
50. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD and Huber R. Structure of 20S proteasome from yeast at 2.4Å resolution. Nature. 1997; 386:463-471.
51. Trott O and Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31:455-461.
52. Vetrivel U and Pilla K. Open discovery: An integrated live Linux platform of Bioinformatics tools. Bioinformation 2008; 3:144-146.
53. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102:1555-1577.